Jiang, H., Lwin, T., Zhao, X., Ren, Y., Li, G., Moscinski, L., . . . Tao, J. (2018). Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma (MCL). Br J Haematol.
Citación estilo ChicagoJiang, Huijuan, Tint Lwin, Xiaohong Zhao, Yuan Ren, Grace Li, Lynn Moscinski, Bijal Shah, and Jianguo Tao. "Venetoclax As a Single Agent and in Combination With PI3K-MTOR1/2 Kinase Inhibitors against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma (MCL)." Br J Haematol 2018.
Cita MLAJiang, Huijuan, et al. "Venetoclax As a Single Agent and in Combination With PI3K-MTOR1/2 Kinase Inhibitors against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma (MCL)." Br J Haematol 2018.